ArticleMolecular and cellular biology2001
Use of chromatin immunoprecipitation to clone novel E2F target promoters.
Article in Molecular and cellular biology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 162 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
162 citing papers in PubMed, 379 citations in OpenAlex.
- Characterization of a novel long noncoding RNA, SCAL1, induced by cigarette smoke and elevated in lung cancer cell lines.American journal of respiratory cell and molecular biology · 2013Trial
- The Algorithm for Reversible Jump Inference of Motifs.bioRxiv : the preprint server for biology · 2025Article
- BECLIN-1/BECN1 at the barrier: a gatekeeper of epithelial and endothelial homeostasis.Autophagy reports · 2025Review
- Examining NF-κB genomic interactions by ChIP-seq and CUT&Tag.bioRxiv : the preprint server for biology · 2024Article
- Author Correction: EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer.The EMBO journal · 2024Article
- Transcriptomic era of cancers in females: new epigenetic perspectives and therapeutic prospects.Frontiers in oncology · 2024Review
- Review
- Genome-wide binding analysis of 195 DNA binding proteins reveals "reservoir" promoters and human specific SVA-repeat family regulation.PloS one · 2021Article
- AP-1 imprints a reversible transcriptional programme of senescent cells.Nature cell biology · 2020Article
- Article
- Isolation of secreted proteins from Drosophila ovaries and embryos through in vivo BirA-mediated biotinylation.PloS one · 2019Article
- Detection of E2F-DNA Complexes Using Chromatin Immunoprecipitation Assays.Methods in molecular biology (Clifton, N.J.) · 2018Article
- Analysis of the c-KIT Ligand Promoter Using Chromatin Immunoprecipitation.Journal of visualized experiments : JoVE · 2017Article
- RNA helicase DDX3 maintains lipid homeostasis through upregulation of the microsomal triglyceride transfer protein by interacting with HNF4 and SHP.Scientific reports · 2017Article
- Autophagy and the Cell Cycle: A Complex Landscape.Frontiers in oncology · 2017Review
- The transcriptional repressor ICER binds to multiple loci throughout the genome.Biochemical and biophysical research communications · 2016Article
- Role of EZH2 histone methyltrasferase in melanoma progression and metastasis.Cancer biology & therapy · 2016Review
- Targeting Enhancer of Zeste Homolog 2 as a promising strategy for cancer treatment.World journal of clinical oncology · 2016Article
- The Retinoblastoma Tumor Suppressor Protein (pRb)/E2 Promoter Binding Factor 1 (E2F1) Pathway as a Novel Mediator of TGFβ-induced Autophagy.The Journal of biological chemistry · 2016Article
- Brg1 coordinates multiple processes during retinogenesis and is a tumor suppressor in retinoblastoma.Development (Cambridge, England) · 2015Article
102 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
We have taken a new approach to the identification of E2F-regulated promoters. After modification of a chromatin immunoprecipitation assay, we cloned nine chromatin fragments which represent both strong and weak in vivo E2F binding sites. Further characterization of three of the cloned fragments revealed that they are bound in vivo not only by E2Fs but also by members of the retinoblastoma tumor suppressor protein family and by RNA polymerase II, suggesting that these fragments represent promoters regulated by E2F transcription complexes. In fact, database analysis indicates that all three fragments correspond to genomic DNA located just upstream of start sites for previously identified mRNAs. One clone, ChET 4, corresponds to the promoter region for beclin 1, a candidate tumor suppressor protein. We demonstrate that another of the clones, ChET 8, is strongly bound by E2F family members in vivo but does not contain a consensus E2F binding site. However, this fragment functions as a promoter whose activity can be repressed by E2F1. Finally, we demonstrate that the ChET 9 promoter contains a consensus E2F binding site, can be activated by E2F1, and drives expression of an mRNA that is upregulated in colon and liver tumors. Interestingly, the characterized ChET promoters do not display regulation patterns typical of known E2F target genes in a U937 cell differentiation system. In summary, we have provided evidence that chromatin immunoprecipitation can be used to identify E2F-regulated promoters which contain both consensus and nonconsensus binding sites and have shown that not all E2F-regulated promoters show identical expression profiles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.